The Incretin-Glucagon Axis: GLP-1, GIP, and Glucagon in Hunger and Energy Homeostasis
This article is written for research and educational purposes only. The compounds, peptides and molecules discussed have not been approved for human use by any regulatory authority. Nothing in this article constitutes medical advice, a treatment recommendation, or a dosage guideline. Helix supplies research-grade compounds exclusively for in vitro and preclinical research use.
Every time you eat a meal, your gut orchestrates a biochemical response of remarkable precision. Within minutes of food entering the small intestine, a cascade of peptide hormones is released into the bloodstream and dispatched to the brain, pancreas, stomach, and liver. These hormones do not just manage blood sugar. They determine how full you feel, how quickly your stomach empties, how much energy you store, and when you want to eat again.
Three of the most important players in this system are GLP-1, GIP, and glucagon. Understanding them is not just academic exercise. These three peptides are the mechanistic foundation for the most effective class of obesity drugs ever developed, and they explain why those drugs work in ways that no previous medication could match.
GLP-1: The Satiety Signal
Glucagon-like peptide-1 (GLP-1) is secreted by L-cells scattered throughout the gut epithelial lining, primarily in the ileum and colon, in response to nutrient ingestion. Its natural half-life in circulation is just 1 to 2 minutes, rapidly degraded by the enzyme DPP-4, which is why its physiological effects are concentrated in the period immediately after eating. [Parker, Gribble & Reimann, Experimental Physiology, 2014]
GLP-1's primary actions include stimulating glucose-dependent insulin secretion, inhibiting glucagon release, slowing gastric emptying so nutrients enter the bloodstream more slowly, and signaling satiety to the brain. The combination of these effects means a single peptide simultaneously lowers blood sugar after meals and reduces the desire to eat more.
The brain is central to how GLP-1 suppresses appetite. Research has identified that GLP-1 receptor agonists act in part via AgRP neurons in the hypothalamus, the population most directly responsible for hunger signaling. When GLP-1 receptors in the arcuate nucleus are activated, AgRP neuron activity drops, and hunger diminishes at the neural level. [Ling et al., PMC, 2025]
GIP: The Underestimated Incretin
Glucose-dependent insulinotropic polypeptide (GIP) is the other major incretin hormone, secreted by K-cells in the upper small intestine in response to fat and carbohydrate ingestion. For decades it was viewed primarily as an insulin secretagogue with modest relevance compared to GLP-1.
Recent research has dramatically revised this picture. A study using in vivo fiber photometry found that GIP, but not GLP-1, is required for normal nutrient-mediated inhibition of AgRP neurons, making GIP the physiologically necessary signal for meal-induced appetite suppression, while GLP-1 provides additional pharmacological suppression at therapeutic doses. [Ling et al., PMC, 2025]
GIP also plays an important role in moderating the side effects of GLP-1 receptor agonism. Research has shown that GIP receptor activation reduces the recruitment of brainstem cholecystokinin neurons responsible for GLP-1-induced nausea, which helps explain why dual GIP/GLP-1 agonists like tirzepatide produce greater weight loss with better tolerability than GLP-1 agonists alone. [Anorectic effects of GLP-1 RAs, PMC, 2021]
Glucagon: Not Just the Opposite of Insulin
Glucagon is produced by alpha cells in the pancreas and is primarily known as insulin's counterpart: while insulin lowers blood glucose, glucagon raises it by triggering glucose release from the liver. But glucagon's metabolic role is considerably richer than this opposition suggests.
In the liver, glucagon promotes fatty acid oxidation and ketone production. At the level of adipose tissue, it stimulates lipolysis. In the brain, glucagon receptors are present in regions involved in appetite regulation. High glucagon activity suppresses food intake and promotes energy expenditure, which is why glucagon receptor agonism is being incorporated into next-generation multi-hormone therapies.
The Triple Agonist Frontier
The convergence of these three peptide systems is now shaping the next generation of metabolic therapies. Researchers are already testing triple-agonist drugs such as retatrutide, which simultaneously targets GLP-1, GIP, and glucagon receptors. Early clinical data suggests even greater weight loss and metabolic benefits than dual agonists. [UAB Research News, 2026]
Even more ambitious approaches are being explored, including five-receptor agonists combining incretin hormones with nuclear hormone receptor targets. The pace of innovation in this space is accelerating rapidly, and the mechanistic foundation for all of it is these three gut peptides that have been regulating human metabolism since the earliest stages of vertebrate evolution.
The Bottom Line
GLP-1, GIP, and glucagon are not simply diabetes drugs or weight-loss mechanisms. They are the endogenous peptide system through which the body manages energy balance meal by meal. Their interactions with the brain, pancreas, liver, and adipose tissue constitute one of the most sophisticated metabolic coordination systems in human physiology.
Understanding them explains not just why semaglutide and tirzepatide work, but why hunger is so biologically stubborn, why diets alone so often fail, and why the future of metabolic medicine is increasingly a story about peptides.
This article is for informational purposes only and does not constitute medical advice.
Sources
1. Parker, Gribble & Reimann, Experimental Physiology, 2014 — PMC4405037
2. Ling et al., PMC, 2025 — PMC12578400
3. Anorectic effects review, PMC, 2021 — PMC8689241
4. UAB News, GLP-1 Revolution Research, 2026 — View article